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Abstract
Glutamate is believed to be an excitatory amino acid neurotransmitter in the retina. Enzymes for glutamate metabolism,
such as glutamate dehydrogenase, ornithine aminotransferase, glutaminase, and aspartate aminotransferase (AAT), exist
mainly in the mitochondria. The abnormal increase of intracellular calcium ions in ischemic retinal cells may cause an influx
of calcium ions into the mitochondria, subsequently affecting various mitochondrial enzyme activities through the activity of
mitochondrial calpain. As AAT has the highest level of activity among enzymes involved in glutamate metabolism, we
investigated the change of AAT activity in ischemic and hypoxic rat retinas and the protection against such activity by
calpain inhibitors. We used normal RCS (rdy/rdy) rats. For the in vivo studies, we clamped the optic nerve of anesthetized
rats to induce ischemia. In the in vitro studies, the eye cups were incubated with Locke’s solution saturated with 95% N2/5%
CO2. The activity of cytosolic AAT (cAAT) was about 20% of total activity, whereas mitochondrial AAT (mAAT) was
about 75% in rat retina. Ninety minutes of ischemia or hypoxia caused a 20% decrease in mAAT activity, whereas cAAT
activity remained unchanged. To examine the contribution of intracellular calcium ions to the degradation of mAAT, we
used Ca2-free Locke’s solution containing 1 mM EGTA, ryanodine (Ca2 channel blocker), and thapsigargin (Ca2-
ATPase inhibitor). In the present study, thapsigargin in Ca2-free Locke’s solution, but not ryanodine in this solution, was
found to prevent AAT degradation. AAT degradation was also prevented by calpain inhibitors (Ca2-dependent protease
inhibitor) such as calpeptin at 1 nM, 10 nM, 0.1 WM, 1 WM and 10 WM, and by calpain inhibitor peptide, but not by other
protease inhibitors (10 WM leupeptin, pepstatin, chymostatin). Additionally, we determined the subcellular localization of
calpain activity and examined the change of calpain activity in ischemic rat retinas. Our results suggest that decreased activity
of mAAT in ischemic and hypoxic rat retinas might be evoked by the degradation by calpain-catalyzed proteolysis in
mitochondria. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Considerable evidence indicates that glutamate
plays an excitatory neurotransmitter role for gluta-
mate in the mammalian central nervous system [1^3],
stimulating glutamate receptors to increase the per-
meability of the cell membrane. The released gluta-
mate from presynaptic nerve terminals is taken up by
Mu«ller cells and converted to glutamine by glutamine
synthetase. Glutamine is released by Mu«ller cells and
is taken up by neurons for deamination to glutamate
by phosphate-activated glutaminase [4]. This process
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is generally known as the glutamine cycle. Because
glutamate does not readily cross the blood-brain bar-
rier, it must be synthesized within the central nervous
system. It is widely assumed that neurons synthesize
glutamate themselves, using aspartate or precursors
derived from the Krebs cycle [5]. Aspartate amino-
transferase (AAT) catalyzes the interconversion of
glutamate and oxaloacetate with aspartate and K-ke-
toglutarate.
Ischemia reportedly produces a massive e¥ux of
glutamate. Glutamate couples with NMDA gluta-
mate receptors. It is generally agreed that calcium
conductance linked to the NMDA receptor iono-
phore is responsible for both the plasticity and path-
ology triggered by the receptor [6^8]. Most previous
studies have shown that intracellular calcium ions
play a fundamental role in regulating numerous en-
zyme activities and mediating the e¡ects of hormones
and growth factors that control a wide variety of
cellular processes, such as metabolism, cell di¡eren-
tiation, and secretion. The loss of Ca2 homeostasis
due to excess Ca2 in£ux through voltage-dependent
channels and NMDA receptor-operated channels
and the decrease of Ca2 pumping resulting from
ATP depletion and due to the release of Ca2 from
intracellular stores are believed to result in ischemic
damage. Loss of Ca2 homeostasis may activate
Ca2-dependent enzymes such as proteases, phos-
pholipases [9], and endonucleases, leading to mito-
chondrial damage and cell death resulting from en-
ergy failure.
In the present study, we investigated the change of
AAT activity in ischemic and hypoxic rat retinas.
AAT has the highest activity among the enzymes
for glutamate metabolism [10^17]. The distribution
of AAT activity in retinal layers has been reported
predominantly in the outer plexiform layer and pho-
toreceptor inner segments [18,19]. The outer plexi-
form layer contains photoreceptor terminals and bi-
polar and horizontal cell processes. AAT might play
an important role as a neurotransmitter such as that
of glutamate in the outer plexiform layer [20,21],
although other functions, such as retinal energy me-
tabolism, are possible. The correlation between the
distributions of AAT and malate dehydrogenase
(MDH), an enzyme of aerobic metabolism
[18,19,22], is consistent with AAT involvement in
retinal energy metabolism. We also examined the
contribution of calcium ions to the change of mito-
chondrial AAT (mAAT), using EGTA, ryanodine
(Ca2 channel blocker) and thapsigargin (Ca2-AT-
Pase inhibitor). In addition, we assayed Ca2-de-
pendent protease (calpain) activities of each retinal
fraction under conditions of ischemia and examined
the protective e¡ects against decreased mAAT activ-
ity using Ca2-dependent protease inhibitors (calpain
inhibitor peptide) and other protease inhibitors.
2. Materials and methods
2.1. Preparation of samples
Normal RCS (rdy/rdy) rats [23] weighing 200^
250 g were used. After administering intramuscular
anesthesia, we clamped the left optic nerve with an
aneurysm clip (Mizuho Co. Ltd., Tokyo, Japan) to
stop the blood £ow in retinal vessels. The right eyes
were used as sham-operated controls. After 30, 60 or
90 min of clamping, both eyes were enucleated and
the retinas were separated. Interruption of blood
£ow was con¢rmed ophthalmoscopically, and ammo-
nia concentrations were measured. In the retina, it is
thought that ammonia is mainly converted to gluta-
mine by glutamine synthetase (GS) in retinal Mu«ller
cells. GS, however, does not work e⁄ciently during
ischemia, since this enzyme requires ATP for gluta-
mine formation. We therefore also measured the am-
monia concentration of retinas as an indicator of
ischemia.
The following steps were carried out at 4‡C. The
rat retina was homogenized with 500 Wl of 0.25 M
sucrose using a glass-Te£on homogenizer. The ho-
mogenate was dialyzed with distilled water for 60
min to remove endogenous disturbing substances.
To examine the distribution of AAT in the retina,
we obtained a nuclear fraction, a mitochondrial frac-
tion, a lysosomal fraction, and a microsomal fraction
by di¡erential centrifugation at 600Ug for 5 min,
4500Ug for 10 min, 20 000Ug for 20 min, and
100 000Ug for 60 min, respectively. These were
washed three times by suspending in fresh 0.25 M
sucrose and resedimenting under the same condi-
tions. The supernatant obtained was used as a solu-
ble fraction. Each pellet was resuspended in 500 Wl of
0.25 M sucrose. The AAT activity was found mainly
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in mitochondrial and soluble fractions. The superna-
tant contained mainly cytosolic AAT (cAAT).
To separate the soluble mAAT, the pellet of the
mAAT fraction was disrupted by four freeze-thaw
cycles. The sample was centrifuged at 100 000Ug
for 60 min. The supernatant obtained was used as
the soluble mitochondrial fraction, and the pellet ob-
tained was used as the membrane-bound mitochon-
drial fraction. mAAT activity was found in the mem-
brane-bound mitochondrial fraction.
For in vitro experiments, normal RCS rat eyes
were enucleated following intramuscular anesthesia.
We removed the cornea, lens, and vitreous, and we
obtained the eye cups. The eye cups were incubated
at 37‡C in Locke’s solution (Na 157 mM, Ca2 2.3
mM, Cl3 164.2 mM, HCO33 3.6 mM, HEPES 5 mM,
pH 7.2) and saturated with 95% O2/5% CO2 for 30,
60, or 90 min as control samples. We used glucose-
free Locke’s solution saturated with 95% N2/5% CO2
for 30, 60, or 90 min as hypoxic samples. To obtain
samples for measuring mAAT and cAAT activities,
we used the same methods as described above.
2.2. E¡ects of EGTA, ryanodine, and thapsigargin on
mAAT activity in hypoxic rat retinas
To examine the protective e¡ects of EGTA, rya-
nodine (Ca2 channel blocker), and thapsigargin
(Ca2-ATPase inhibitor) on AAT activity, eye cups
were incubated at 37‡C for 90 min in Ca2-free
Locke’s solution with 1 mM EGTA in Locke’s so-
lution with 1 nM, 100 nM, or 10 WM ryanodine and
in Locke’s solution with 250 nM or 500 nM thapsi-
gargin.
2.3. E¡ects of protease inhibitors on mAAT activity of
hypoxic rat retinas
To examine the protective e¡ects of Ca2-depend-
ent protease inhibitors (calpain inhibitor peptide, cal-
peptin) and other protease inhibitors (pepstatin, leu-
peptin, chymostatin) on AAT activity, the eye cups
under hypoxic condition were incubated in Locke’s
solution with 1 nM, 10 nM, 0.1 WM, 1 WM, or 10 WM
calpain inhibitor peptide (RBI, Natick, MA, USA)
and calpeptin (TOCRIS, Bristol, UK), and 10 WM
pepstatin, leupeptin, or chymostatin (Peptide Insti-
tute, Inc., Osaka, Japan).
2.4. Assay of aspartate aminotransferase activity
Activity of AAT was assayed according to the
modi¢ed method of Godfrey et al. [24,25]. After 60
min of dialysis, 20 Wl (34 Wg protein) of samples was
added to a 30 Wl reaction mixture containing 60 mM
imidazole bu¡er, pH 7.4, 4 mM K-ketoglutarate, 0.7
g/l bovine serum albumin, 1.4 ml/l Triton X-100, and
1.4 mg/l MDH. Each tube was sonicated for 1 min
on the ice, and the reaction was started by adding 10
Wl of substrate solution containing of 160 mM L-as-
partate and 1.44 mM NADH. Samples were incu-
bated at 37‡C for 2 min, then the reaction was
stopped by adding 40 Wl of 0.7 M HCl. After 20
min required to destroy the remaining NADH in
the acid solution, 1 ml indicator solution containing
95 mM Tris-HCl bu¡er, pH 8.5, 860 mM ethanol,
2 mM mercaptoethanol and 11.6 mg/l alcohol dehy-
drogenase were added to each sample. The NAD
was converted to NADH in 30 min. The intensity of
£uorescence of each sample was measured with a
£uorophotometer (excitation: 340 nm; emission:
460 nm).
Protein concentration was measured by the meth-
od of Lowry et al. [26].
2.5. Assay of ammonia concentration
Ten microliters of 7% trichloroacetic acid (TCA)
was immediately added to 60 Wl of the homogenized
solution of the fresh retina. After standing at 4‡C for
15 min, the samples were centrifuged at 10 000 rpm
for 3 min at 4‡C. Distilled water (70 Wl) was added to
30 Wl of the supernatant. The ammonia concentra-
tion was measured by adding 2.9 ml of o-phthaldial-
dehyde/mercaptoethanol reagent. The mixtures were
kept in the dark at room temperature for 45 min and
then intensities of £uorescence were measured with a
£uorophotometer (excitation: 410 nm; emission: 470
nm) [27]. The optical density was converted to am-
monia concentration using the NH4Cl standard
curve.
2.6. Antibody preparation
AAT antibody was prepared by the modi¢ed
method of Altschuler et al. [28]. Commercially avail-
able AAT (Boehringer Mannheim) was electropho-
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resed on sodium dodecyl sulfate polyacrylamide gel
(SDS-PAGE) [29]. Of these, a component of about
45 000 Da is the major band and has been identi¢ed
as the monomeric subunit of AAT [30]. The 45 000
Da component was separated from the other bands
and collected by electrophoresis. Re-electrophoresis
of this band showed a single major component at
45 000 Da. Antibodies were raised against the pre-
pared isolated 45 000 Da component, using two
New Zealand white rabbits. The prepared isolated
45 000 Da component was emulsi¢ed in Freund’s ad-
juvant and injected subcutaneously into the rabbits’
necks. The antisera were collected and characterized.
The collected IgG solution was puri¢ed by an a⁄nity
column (HiTrap NHS-activated, Amersham Pharma-
cia Biotech, Bucks, UK). We obtained the two bands
by immunoblotting of crude rat retina homogenate
(including mitochondrial and soluble fractions) using
rabbit antisera against AAT (the 45 000 Da subunit).
We also used rabbit antisera against rat liver mAAT
(generous gift from Dr. Horio), which have been
produced and characterized elsewhere [31,32]. By
the immunoblotting of rat retina homogenate (only
mitochondrial fraction), one band was obtained with
the rabbit antisera against rat liver mAAT.
2.7. Electrophoresis of AAT and immunoblotting
Gel electrophoresis in the presence of SDS was
performed according to the method of Laemmli
[29] on a 10% polyacrylamide gel. The crude rat ret-
inal homogenates, mitochondrial fraction, and cyto-
solic fraction (10 Wl sample/lane, 170 Wg of protein/
lane) were applied on the gel. Electrophoresis was
carried out for 1 h at 100 V. The ischemic samples
(90 min clamping) were analyzed in the same way.
Western blotting was performed according to Tow-
bin et al. [33]. After electrophoretic transfer of pro-
teins to nitrocellulose membranes (Cellulose Nitrate,
Advantec, Toyo Roshi Kaisha Ltd.), the membranes
were treated with 3% gelatin and 5% skim milk in
PBS for 1 h at 37‡C. We used 1:2000 diluted rabbit
antisera against AAT (the 45 000 Da subunit) and
1:1000 diluted rabbit antisera against rat liver
mAAT as the ¢rst antibody and peroxidase-conju-
gated goat anti-rat IgG antibody as the second anti-
body. The antibodies were diluted with phosphate-
bu¡ered saline (0.14 M NaCl and 10 mM phosphate
bu¡er, pH 7.4) containing 1% bovine serum albumin
and 0.05% Tween 20.
Each incubation time was 1 h at 37‡C. Washing
was performed after each step with phosphate-bu¡-
ered saline containing 0.05% Tween 20.
2.8. Assay of calpain activity
Calpain activity was assayed using Cell Probe LY
Calpain Enzyme Substrate as substrate (Coulter,
Florida, USA). One unit calpain (Sigma Co., St.
Louis, MO, USA) produces an A280 of 0.5 in 30
min at pH 7.5 at 30‡C, measured as TCA-soluble
products using N,N-dimethylated casein as substrate.
Cell Probe LY Calpain Enzyme Substrate is cleaved
by calpain to form a £uorescent product, rhodamine
110, which can be measured by £uorescence quanti-
¢cation techniques. The intensity of £uorescence of
each sample was measured with a £uorophotometer
(excitation: 499 nm; emission: 521 nm). To examine
the initial rate of relative £uorescence intensity
changes as functions of calpain concentration and
incubation time, 50 Wl of Cell Probe LY Calpain
Enzyme Substrate was incubated with various
amounts (0.2^0.5 U) of calpain for various incuba-
tion times (0, 5, 10, 15, 20 and 30 min). We examined
the Ca2 requirement of calpain for the hydrolysis of
Cell Probe LY Calpain Enzyme Substrate by assay-
ing calpain hydrolytic activity at various Ca2 con-
centrations using the Ca2-EGTA bu¡er system.
Samples used were a crude retinal homogenate, a
nuclear fraction, a mitochondrial fraction, a lysoso-
mal fraction, a microsomal fraction and a soluble
fraction. These samples were obtained by dialysis,
di¡erential centrifugation, and by three times wash-
ing, using the same methods as described above.
Fifty microliters of each sample (17 Wg of protein)
was incubated with Cell Probe LY Calpain Enzyme
Substrate at 37‡C. After 15 min of incubation, 1 ml
of ice-cold PBS was added to stop the reaction, and
then the samples were kept on ice for 20 min. The
resulting £uorescence from the hydrolysis of the Cell
Probe LY Calpain Enzyme Substrate provides a
measure of the enzyme activity within a sample. Cal-
pain activity was de¢ned as the di¡erence in proteo-
lytic activity between assays in the presence of CaCl2
or EGTA. To control the free calcium, each sample
fraction was resuspended in 500 Wl of 0.25 M sucrose
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containing 50 mM Tris-HCl, pH 7.5, 1 mM EGTA
or varying amounts of CaCl2.
To con¢rm the contamination of the soluble frac-
tion to a mitochondrial fraction, Western blot anal-
ysis using a soluble fraction as a marker was per-
formed. Each sample, containing approximately 170
Wg of protein/lane, was electrophoresed on 10% SDS
polyacrylamide gels and transferred to a nitrocellu-
lose membrane. Western blot analysis was performed
using the rabbit antisera against AAT (45 000 Da
subunit).
2.9. Immunoprecipitation of calpain activity by
monoclonal antibody to m-calpain
The monoclonal antibody to m-calpain (Alexis
Co., Switzerland) (0.1^10 Wg) and the monoclonal
antibody to glial ¢brillary acidic protein (GFAP)
(Boehringer Mannheim, Germany) (0.1^10 Wg) were
incubated with 5 Wl (8.5 Wg) sample of sonicated and
dialyzed mitochondrial fractions in a total volume of
60 Wl of 0.25 M sucrose containing 50 mM Tris-HCl,
pH 7.5, 5 mM CaCl2. After 2 h at 4‡C, excess goat
anti-mouse IgG (Southern Biotechnology Associates
Inc., USA) was added (40 Wl) and incubated for 18 h
at 4‡C. The samples were centrifuged at 12 000 rpm
for 10 min at 4‡C. Fifty microliters of the superna-
tant was used for assay of calpain activity as de-
scribed above.
3. Results
AAT activity was found to be present in mito-
chondrial and cytosolic fractions by di¡erential cen-
trifugation. Speci¢c activity of crude retinal extract
was 780 þ 8.0 (mean þ S.D., n = 20) nmol/min/mg
protein. The mAAT and cAAT activities were
585 þ 6.5 and 170 þ 7.5 (n = 20) nmol/min/mg crude
retinal protein, respectively. mAAT was 75% of total
retinal AAT activity. Centrifugation at 100 000Ug
for 60 min after four freeze-thaw cycles resulted in
mAAT activity only in the membrane-bound mito-
chondrial fraction.
mAAT and cAAT activities in ischemic rat retinas
are shown in Fig. 1. Ninety minutes of ischemia
caused a 20% decrease in mAAT activity, whereas
cAAT activity remained unchanged. Ischemia for
30, 60, or 90 min of ischemia produced elevated am-
monia concentrations in rat retinas (30 min of ische-
mia: control 6.56 þ 0.31; ischemia, 6.78 þ 0.33 nmol/
mg crude retinal protein; 60 min of ischemia, con-
trol, 6.46 þ 0.51; ischemia, 9.01 þ 0.55 nmol/mg crude
retinal protein; 90 min of ischemia, control,
6.63 þ 0.23; ischemia, 11.4 þ 0.43 nmol/mg crude ret-
inal protein). A similar decrease in AAT activity was
observed in vitro after 90 min of hypoxia. As shown
in Fig. 2, 90 min of hypoxia caused a 20% decrease
Fig. 1. The activity of AAT under ischemic conditions (in
vivo). The optic nerve was clamped to stop the blood £ow in
retinal vessels for di¡erent time periods. After 30, 60, or 90 min
of clamping, rat retinas were separated for immediate analysis.
Details are described in Section 2. (a) Change of mAAT activ-
ity under ischemic conditions (a). As a control, the right eyes
were sham-operated and enucleated after 30, 60, or 90 min. (b)
Change of cAAT activity under ischemic conditions (a). As a
control, the right eyes were sham-operated. Each datum point
shows mean þ S.D. (n = 4). Ninety minutes of ischemia de-
creased mAAT activity signi¢cantly to 80% (t-test, *P6 0.01),
whereas cAAT activity remained unchanged.
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in mAAT activity. The protective e¡ects of EGTA,
ryanodine, and thapsigargin on retinal mAAT were
examined. The percentage of protection against de-
creased mAAT activity in hypoxic rat retinas is
shown in Fig. 3. Decreased mAAT activity was
90% e¡ectively prevented by the addition of 1 mM
EGTA and 250 or 500 nM thapsigargin, but not by
the addition of ryanodine (1 nM to 10 WM).
The protective e¡ects of several protease inhibitors
(pepstatin, leupeptin, chymostatin, calpain inhibitor
peptide, calpeptin) on retinal mAAT were examined.
The percentage of protection against decreased
mAAT activity in hypoxic rat retinas is shown in
Fig. 4. Decreased mAAT activity was approximately
85% prevented by the addition of calpain inhibitor
peptide and calpeptin. The concentrations of calpain
inhibitor peptide and calpeptin for 50% protection
(EC50) of mAAT activity were about 200 nM and
150 nM, respectively. Each EC50 was higher than
each IC50 (100 nM, 30^50 nM) [34^38].
mAAT and cAAT were stained by immunoblots
using the rabbit antisera against AAT (the 45 000
Da subunit). The upper band was cAAT and the
lower band was mAAT (mAAT had a molecular
weight of 44 500 and cAAT had a molecular weight
of 46 000). The mAAT band was also detected by
rabbit antisera against rat liver mAAT. The density
of the mAAT band under hypoxic condition was
lower than that of the control sample mAAT, but
that of the cAAT band did not change (Fig. 5).
To con¢rm the presence of calpain in the retinal
mitochondria, we measured the calpain activities in
the subcellular fractions. Hydrolysis of the Cell
Fig. 2. The activity of AAT under hypoxic conditions (in vitro).
The eye cup was incubated in Locke’s solution saturated with
95% N2/5% CO2 for 30, 60, or 90 min. (a) Change of mAAT
activity under hypoxic conditions (a). As a control, the eye cup
was incubated in Locke’s solution saturated with 95% O2/5%
CO2 for 30, 60, or 90 min. (b) Change of cAAT activity under
hypoxic conditions (a). As a control, the eye cup was incu-
bated in Locke’s solution saturated with 95% O2/5% CO2 for
30, 60, or 90 min. Each datum point shows mean þ S.D. (n = 4).
Ninety minutes of hypoxia decreased membrane-bound mAAT
signi¢cantly to 80% (t-test, *P6 0.01), whereas cAAT activity
remained unchanged.
Fig. 3. The e¡ects of EGTA, ryanodine, and thapsigargin on
retinal mAAT activity under hypoxic conditions in vitro. The
concentrations of reagent used were 1 mM EGTA, 1 nM, 100
nM and 10 WM ryanodine, and 500 nM thapsigargin. The re-
agents were added to Locke’s solution saturated with 95% N2/
5% CO2. One hundred percent protection represented no degra-
dation of the enzyme. Each datum point shows mean þ S.D.
(n = 4). Treatment with 1 mM EGTA and 500 nM thapsigargin
protected against enzyme activity, but ryanodine (1 nM to
100 WM) did not.
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Probe LY Calpain Enzyme Substrate was found to
be linear with calpain concentration (0.2^0.5 U) (Fig.
6). After 20 min incubation, the relative £uorescence
reached a plateau (Fig. 7). Five millimolar or more
calcium ion was required for maximum reaction of
calpain (Fig. 8). Total retinal calpain activity was
145 þ 7.5 (mean þ S.D., n = 20) U/h/mg protein. The
amounts of calpain activity found in the soluble frac-
tion (60%), the mitochondrial fraction (30%) and the
microsomal fraction (10%) are shown in Fig. 9. To
con¢rm the contamination of cytosolic cAAT to a
mitochondrial fraction, Western blot analysis of
AATs using a soluble fraction and mitochondrial
fraction was performed. We used rabbit antisera
Fig. 4. The e¡ects of protease inhibitors on retinal mAAT ac-
tivity under hypoxic conditions in vitro. The concentrations of
reagents used were 10 WM pepstatin; 10 WM leupeptin; 10 WM
chymostatin; 1 nM, 10 nM, 0.1 WM, 1 WM, and 10 WM calpain
inhibitor peptide and calpeptin.The reagents were added to
Locke’s solution saturated with 95% N2/5% CO2. One hundred
percent protection represented no degradation of the enzyme.
Each datum point shows mean þ S.D. (n = 4). Treatment with
calcium-activated neutral protease inhibitors (calpain inhibitor
peptide and calpeptin) speci¢cally protected against enzyme ac-
tivity.
C
Fig. 5. Western blot analysis of AAT in rat retina. Crude rat
retinal homogenate, the soluble fraction and the mitochondrial
fraction, each containing approximately 170 Wg of protein/lane,
were electrophoresed on 10% SDS polyacrylamide gels and
transferred to a nitrocellulose membrane. Western blot analysis
was performed using anti-AAT antisera. (A) Immunostaining
using the rabbit antisera against AAT (45 000 Da subunit).
Lane a, molecular weight standards; lane b, crude retinal ho-
mogenate; lane c, soluble fraction; lane d, commercial AAT.
(B) Immunostaining using the rabbit antisera against AAT
(45 000 Da subunit). Lane a, molecular weight standards; lane
b, soluble fraction (control) ; lane c, soluble fraction (90 min.
hypoxia). (C) Immunostaining using the rabbit antisera against
rat liver mAAT. Lane a, molecular weight standerds; lane b,
mitochondrial fraction (control) ; lane c, mitochondrial fraction
(90 min hypoxia).
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against AAT (the 45 000 Da subunit), which recog-
nize both mAAT and cAAT. We could obtain only
one band of mAAT from a mitochondrial fraction,
and the possibility of cytosolic contamination to mi-
tochondrial fractions was eliminated (Fig. 10).
Immunoprecipitation of calpain activity in a mito-
chondrial fraction was carried out by the monoclonal
antibody to m-calpain. The monoclonal antibody to
GFAP was used as a control. Fig. 11 shows the
results of the precipitation. Approximately 80% of
the calpain activity was precipitated by the mono-
clonal antibody to m-calpain. The result indicates
that our Ca2-dependent activity is mainly attributed
to m-calpain activity.
After 90 min of clamping, mitochondrial calpain
activity showed a 2.5-fold increase, but cytosolic cal-
pain activity decreased to 60% compared with each
activity (Fig. 12).
4. Discussion
It is widely accepted that glutamate acts as a neu-
rotransmitter in the central nervous system [1^3].
Fig. 6. Determination of the initial rate of relative £uorescence
intensity change. Fifty microliters of Cell Probe LY Calpain
Enzyme Substrate was incubated with various amounts (0.2^0.5
U) of calpain in the standard kinetic assay, and the initial rate
of £uorescence intensity change was determined and plotted as
a function of calpain concentration. One unit calpain (Sigma,
St. Louis, MO, USA) produces an A280 of 0.5 in 30 min at pH
7.5 at 30‡C, measured as TCA-soluble products using N,N-di-
methylated casein as substrate.
Fig. 7. Initial rate of relative £uorescence intensity change as a
function of calpain concentration and incubation time. Fifty
microliters of Cell Probe LY Calpain Enzyme Substrate was in-
cubated with various amounts (0.2^0.5 U) of calpain. After in-
cubation for 0, 5, 10, 15, 20 and 30 min, the reaction was
stopped by adding 1 ml ice-cold PBS for 20 min. Then the £uo-
rescence intensity was measured and normalized to the values
obtained with identically treated samples, without calpain. Da-
tum points represent mean þ S.D. for four experiments.
Fig. 8. Ca2 requirement of calpain for the hydrolysis of Cell
Probe LY Calpain Enzyme Substrate. Assays of calpain hydro-
lytic activity were performed at various Ca2 concentrations us-
ing the Ca2-EGTA bu¡er system.
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AAT has the highest activity among the enzymes for
glutamate metabolism in the rat retina. The present
study showed that mAAT activity decreased under
ischemic or hypoxic conditions. Such a decrease of
mAAT activity would mean serious injury for retinal
functions of metabolism and neurotransmission. Elu-
cidation of the mechanism of this decrease might be
helpful for understanding the regulation of AAT in
the retina and its contribution to alleviation of ische-
mic injury.
In the present study, the mAAT degradation under
hypoxic conditions was decreased by about 90% in
the presence of the endoplasmic reticulum Ca2-
ATPase inhibitor, thapsigargin in Ca2-free Locke’s
solution with EGTA, but not by ryanodine. These
results indicate that decreased mAAT activity may be
Ca2-dependent. It is widely believed that intracellu-
lar Ca2 plays a fundamental role in the regulation
of enzyme activation. Under ischemic conditions, the
intracellular calcium level is elevated through volt-
age-dependent and NMDA receptor-operated chan-
nels. A decrease of Ca2 pumping results from ATP
depletion and the release of Ca2 from intracellular
stores [6^8]. Most previous studies have shown ele-
Fig. 9. Subcellular distribution of calpain activity in rat retina.
Details are described in Section 2. To examine the distribution
of calpain in the retina, we obtained the nuclear fraction, the
mitochondrial fraction, the lysosomal fraction, and the microso-
mal fraction by di¡erential centrifugation. Total retinal calpain
activity was 145 þ 7.5 (mean þ S.D., n = 20) U/h/mg crude retinal
protein. The amount of calpain activity found in the soluble
fraction was 60%, that in the mitochondrial fraction was 30%,
and that in the microsomal fraction was 10%.
Fig. 10. Western blot analysis of AAT in rat retina. To con¢rm
the contamination of cytosolic cAAT to mitochondrial fraction,
Western blot analysis was performed. We used rabbit antisera
against AAT (the 45 000 Da subunit), which recognize both
mAAT and cAAT. Lane a, molecular weight standards; lane b,
soluble fraction; lane c, mitochondrial fraction. We could ob-
tain only one band of mAAT from the mitochondrial fraction,
and the possibility of cytosolic contamination to mitochondrial
fractions was eliminated.
Fig. 11. Immunoprecipitation of calpain activity by monoclonal
antibody to m-calpain. The monoclonal antibodies (0.1^10 Wg)
to m-calpain or GFAP were incubated with 5 Wl (8.5 Wg) of
sonicated and dialyzed mitochondrial fractions. When a precipi-
tation had formed, these samples were centrifuged at 12 000
rpm for 10 min at 4‡C. Fifty microliters of the supernatant ob-
tained was used for assay of calpain activity as described in
Section 2. Approximately 80% of the calpain activity was pre-
cipitated by the monoclonal antibody to m-calpain (b). The
monoclonal antibody to GFAP was used as a control (a).
BBAMCR 14490 29-6-99
S. Endo et al. / Biochimica et Biophysica Acta 1450 (1999) 385^396 393
vated levels of intracellular Ca2 under ischemic con-
ditions. This loss of Ca2 homeostasis then triggers
cellular events that lead to cell damage and death.
The intracellular calcium stores from which calcium
is released contain three major components: pumps
which sequester calcium, binding proteins (such as
calsequestrin and calreticulin) which store calcium,
and speci¢c inositol (1,4,5)-triphosphate receptor
(IP3R) or ryanodine receptor (RyR) channels which
release calcium back into the cytosol. Ryanodine re-
leases Ca2 through the RyR, which is negatively
regulated by calcium-calmodulin (Ca-CaM). RyR
also responds to an increase in the intracellular con-
centration of Ca2, thereby mediating Ca2-induced
Ca2 release (CICR) [39]. These receptors are nor-
mally located on modi¢ed portions of the endoplas-
mic reticulum. The distribution of such IP3-sensitive
or ryanodine-sensitive calcium stores varies consider-
ably among cells. Some cells have either ryanodine-
sensitive stores or IP3-sensitive stores, whereas others
contain both [40,41]. Little is known as yet about the
exact localization and mechanism of Ca2 stores in
retinal cells [42,43]. In this study, under hypoxic con-
ditions, it was suggested that the release of Ca2 may
occur from thapsigargin-sensitive stores, because the
elevation of intracellular Ca2 concentration was
protected by the depletion of Ca2 from Ca2 stores
using thapsigargin (Ca2-ATPase inhibitor), but not
by ryanodine. It was also suggested that RyR might
be negatively regulated by intracellular Ca2 concen-
tration (due to CICR) and by Ca-CaM under hy-
poxic conditions.
The present study showed that 90 min of ischemia
or hypoxia caused a 20% decrease in mAAT activity.
Reportedly the distribution of AAT activity in retinal
layers is found predominantly in the outer plexiform
layer and photoreceptor inner segments [18,19]. Most
previous studies showed that retinal ischemia thinned
the inner retinal layers and reduced the number of
cells in those layers, but not in the photoreceptor
nuclear layer. However, it should be noted that the
photoreceptor segments were shorter and more dis-
organized than normal [44]. Therefore, the photore-
ceptor cells might be sublethally a¡ected by the cy-
totoxic processes and this e¡ect could be due either
to the photoreceptors themselves or to their interact-
ing Mu«ller cells or retinal pigment cells. This suggests
that a 20% decrease in mAAT activity by a 90 min
ischemic insult might be induced by the damage of
speci¢c cells. This decrease was inhibited by calpain
inhibitor but not by leupeptin and other protease
inhibitors. Calpain, a calcium-activated neutral pro-
tease ubiquitously present in animal cells, has been
Fig. 12. Activity of calpain in hypoxic rat retina. After 90 min
of clamping, rat retinas were separated for immediate analysis.
Details are described in Section 2. (a) Change of mitochondrial
calpain activities under hypoxic conditions (a). (b) Change of
cytosolic calpain activities under ischemic conditions (b). Ninety
minutes of ischemia mitochondrial calpain activity resulted in a
2.5-fold increase (t-test, *P6 0.05), whereas cytosolic calpain
activity decreased signi¢cantly to 60% (t-test, *P6 0.05).
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implicated in a large variety of cellular processes [45].
Reportedly, the nature of calpain-catalyzed proteol-
ysis is not digestive, but proceeds in a limited man-
ner, resulting in alteration of the biochemical and
structural parameters of the substrate proteins [46^
48]. The physiological behavior of calpain in cells,
however, has remained unclear. Histochemical stud-
ies have indicated that calpain is present in all neu-
rons and can be detected in the inner and outer seg-
ments of the photoreceptor cells, the outer and inner
parts of the Mu«ller cells corresponding to the outer
and inner limiting membranes, and the outer and
inner plexiform layers in the rabbit retina [49]. In
this study we determined the amount of calpain ac-
tivity in the soluble fraction, the mitochondrial frac-
tion and the microsomal fraction and found that 90
min of ischemia resulted in a 2.5-fold increase in
mitochondrial calpain activity. It is therefore sug-
gested that under the hypoxic condition in this study,
the activation of calpain is likely to occur because of
the elevated level of intracellular Ca2, and that the
decrease of mAAT activity may have been evoked by
the degradation of mAAT due to the activation of
calpain-catalyzed proteolysis in mitochondria.
We did not, however, ¢nd an obvious decrease in
cAAT activity under hypoxic conditions. Unchanged
cAAT activity can be explained by one of the follow-
ing hypotheses: ¢rst, that cAAT is not recognized by
calpain as a substrate; second, that cAAT does not
exist near activated calpain; or third, that under is-
chemic conditions Ca2 concentration is insu⁄cient
for calpain activation in cytosol.
Great di¡erences in sequence (peptides) have been
found between mAAT and cAAT [50,51]. Substrate
speci¢city [52] and the preferred sequence of cleavage
by calpain [53] have not been elucidated. A large
variety of cellular proteins have been reported to
be subject to cleavage by calpain [48]. We cannot
eliminate our ¢rst hypothesis that calpain might
not recognize cAAT as a substrate.
It has been reported that neutrophils and erythro-
cytes that bind calpain to membranes appear to play
important roles in the expression of proteolytic ac-
tivity at physiological Ca2 concentration [54^57].
Calpain results in degradation of membrane-bound
substrates or intracellular protein substrates. In the
presence of a pathologically high Ca2 concentration
calpain might bind to the membrane and prefer
membrane-bound protein to proteolysis. In this
study, mAAT activity was found in the membrane-
bound mitochondrial fraction. Most likely, cAAT
does not exist near activated calpain, contrary to
our second hypothesis.
Ca2 accumulation in the mitochondria occurs
during ischemia [58^61]. In this study, however,
Ca2 concentration in cytosol did not change signi¢-
cantly. It is thought that mitochondria play a part in
intracellular calcium regulation in pathological
states. If this is so, unchanged cAAT can also be
explained by the third hypothesis, namely, that the
level of Ca2 is insu⁄cient for calpain activation in
cytosol under intracellular Ca2 regulation.
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